A little-known biotech’s high-stakes cancer bet just paid off and its shares doubled
CNBC Markets · Tue, 03 Nov 2026 09:35:47 GMT
Read the full story at CNBC Markets ↗OmniFin Portal's take
Excerpt from CNBC Markets: “Genmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.”
Rule-based headline sentiment: Bullish
More Stocks headlines
The 'poison pill' ballot measure that could kill the California billionaire tax— CNBC Markets‘It seems bizarre’: We’re in our 80s with $950,000 in traditional IRAs. Why is our adviser pushing Roth conversions?— MarketWatchCrude oil prices fall for second day as market hopes for diplomatic resolution to Iran war— CNBC MarketsThe Texas governor’s race might be a make-or-break contest for a wobbling AI trade— MarketWatch
New to the fundamentals behind stories like this?
OmniFin Academy covers money basics, risk management, and reading markets — free, self-paced, no sign-up required.
Start OmniFin Academy →